Nobelpharma Signs License Agreement for ProBioGen’s Vaccine Manufacturing Platform

Published on: 

Nobelpharma has come to terms on an agreement to use ProBioGen’s vaccine manufacturing platform AGE1.CR.plX.

On August 12, 2021, German contract development and manufacturing organization (CDMO) ProBioGen announced that Japanese pharmaceutical company Nobelpharma had signed a license agreement to use ProBioGen’s vaccine manufacturing platform AGE1.CR.plX to develop Nobelpharma’s lead vaccine.

The appeal of the manufacturing platform is that it is designed as a true cell suspension line. Because it grows in a chemically defined medium, it is free of any adventitious agents. Consequently, cultivation can be done in large bioreactors, resulting in reduced lead times and a more controlled production process in closed systems.

Established in 2003, Nobelpharma has developed 18 new drugs and one new medical product with a focus on products for underserved patient populations. AGE.CR.plX will be used in the development of their viral vaccine.


"Cell-based systems for vaccine production offer a cost-effective, efficient and flexible alternative to traditional vaccine production,” said Gabriele Schneider, chief business officer at ProBioGen, in a company press release. “With the AGE1.CR.pIX, we have created an exceptionally robust and scalable system, which is becoming increasingly important and we are pleased about the increased demand."

Source: ProBioGen